Centro de Investigación Biomédica en Red

What Centro de Investigación Biomédica en Red does

Centro de Investigación Biomédica en Red (CIBER) is a public biomedical research consortium created in 2006 by the Instituto de Salud Carlos III (ISCIII) under Spain's Ministry of Science, Innovation and Universities, and co-financed with European FEDER and FSE funds. Headquartered in Madrid, it is Spain's largest coordinated biomedical research network, connecting 513 research groups across 105 consortium institutions and 5,654 affiliated researchers organized into 13-14 thematic disease areas (cancer, cardiovascular, neurodegenerative, respiratory, rare diseases, infectious diseases, diabetes/obesity, liver/digestive, mental health, epidemiology, bioengineering/biomaterials/nanomedicine, healthy aging, and others). Its core technology infrastructure includes the NANBIOSIS ICTS platform (one of 29 MINECO-recognized Singular Scientific and Technical Infrastructures), the ISO9001:2015 Pulmonary Biobank, bioinformatics platforms supporting omics and precision medicine, the IMPaCT Cohort and IMPaCT Genomic infrastructures, and the SpadaHC hereditary cancer variant database.

CIBER's product/service portfolio spans technology platforms (NANBIOSIS, Pulmonary Biobank, CIBERINFEC-BIPLAT), extensive patent families covering gene therapies, CAR T-cells, nanoparticles for cancer immunotherapy, diagnostic devices, and clinical decision support software, information platforms (SpadaHC, MAPER), and spin-off vehicles (EpiDisease). Its business model is wholly public-sector: core institutional funding from ISCIII is supplemented by European Commission competitive grants (H2020, Horizon Europe, ERC, IMI2), ISCIII's AES action grants, and AEI national projects. The consortium does not commercialize services through traditional pricing; instead it engages in cooperative research agreements, technology licensing, and contract services with healthcare companies, with the National Health System as the primary end-beneficiary. Distribution and outreach run through institutional website, annual reports (2013-2025), the podcast 'La Ciencia de lo Singular', scientific culture programs, press releases, conferences, and a Technology Transfer portal.

Name

Centro de Investigación Biomédica en Red

Legal name

CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED, M.P.

Website

https://ciberisciii.es

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Centro de Investigación Biomédica en Red (CIBER) is a public Spanish biomedical research consortium under ISCIII that coordinates 513 research groups across 105 institutions and 13-14 disease-focused thematic areas, transferring research results to the National Health System.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYEDAHAGAI

Biomedical Sciences & Medical Research Institutes (University-Based)

Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities

Keywords

• Biomedical research
• Clinical research services
• Translational medicine
• Genomic research networks
• Public health research

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Public Institutional Funding: Core funding from Instituto de Salud Carlos III (ISCIII) under the Ministry of Science, Innovation and Universities. The consortium is co-financed with FEDER (European Regional Development Fund) and FSE (European Social Fund) resources.
2. Competitive Research Project Funding: Funding obtained through competitive calls including European Commission grants (H2020, ERC, Horizon Europe), ISCIII Action Strategic in Health (AES), and national research agency (AEI) projects

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Centro de Investigación Biomédica en Red (CIBER) is a public biomedical research consortium that coordinates collaborative research across 13 thematic areas (rare diseases, cancer, cardiovascular, neurodegenerative, diabetes, obesity, mental health, respiratory, hepatic, infectious, bioengineering, epidemiology, and healthy aging). It connects 513 research groups across 105 Spanish institutions, providing shared technology platforms (NANBIOSIS, biobanks, bioinformatics), technology transfer services, and access to precision medicine infrastructure (IMPaCT).

Product overview

Centro de Investigación Biomédica en Red (CIBER) is a public research consortium dependent on ISCIII comprising 13 thematic areas with 5,654 researchers across 513 groups. The organization operates as a multi-module platform structure providing technology transfer services through technology platforms (NANBIOSIS ICTS, Pulmonary Biobank, Bioinformatics platforms), technology offerings across all thematic areas, and spin-off companies. The core portfolio includes discovery tools, diagnostic technologies, medical devices, gene therapies, and software tools developed by CIBER-BBN, CIBERONC, CIBERDEM, CIBERSAM, CIBEROBN, CIBERER, CIBERCV, CIBEREHD, CIBERNED, and CIBERINFEC areas, complemented by information platforms like SpadaHC (hereditary cancer database) and MAPER (rare disease map), with EpiDisease as the first CIBER spin-off providing epigenetic diagnostic solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• NANBIOSIS ICTS Platform Comprehensive platform for biomedical research providing synthesis, characterization, and in vivo experimentation services, available to national and international researchers.
• Pulmonary Biobank Consortium Transversal, public, non-profit structure providing high-quality biological samples and clinical data for national and international researchers in respiratory diseases, ISO9001:2015 certified.
• CIBERINFEC-BIPLAT Bioinformatics Platform Computational platform providing advanced bioinformatics environment and resources for CIBERINFEC research groups to develop innovative strategies for infectious disease analysis.
• SpadaHC - Spanish Database for Hereditary Cancer Web platform enabling Spanish genetic diagnostic laboratories to share variant data in hereditary cancer genes, promoting consistent variant classification across laboratories.
• MAPER - Interactive Map for Rare Diseases Interactive map showing rare disease research projects and resources across the CIBERER network.
• EpiDisease Spin-off First CIBER spin-off company providing epigenetic diagnostic tools, characterization of new epigenetic drugs, and translational research stimulation to improve health and wellness.
• IMPaCT Precision Medicine Infrastructure Precision medicine infrastructure coordinating Predictive Medicine (IMPaCT Cohort) and Genomic Medicine (IMPaCT Genomic) programs; CIBER coordinates two of three IMPaCT infrastructures.
• SEED-ALS Research Network Collaborative project for ALS research, recruiting over 600 patients and constituting the largest ALS research network in Spain.

Quantifiable outcome

• 513 research groups coordinated across the network
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• AstraZenecacoreStrategic or Co-development Partner · 21 June 2026Agreement to promote respiratory disease research in Spain, combining AstraZeneca's pharmaceutical capabilities with CIBER's research network infrastructure for respiratory diseases (CIBERES)
• Instituto de Salud Carlos III (ISCIII)coreStrategic or Co-development PartnerParent organization that created and funds the CIBER consortium. ISCIII operates under the Ministry of Science, Innovation and Universities and promotes health research in Spain.
• European Commission (FEDER/FSE)coreStrategic or Co-development PartnerEuropean regional development and social funds providing co-financing for the CIBER consortium operations and research activities.
• EpiDiseaseminorStrategic or Co-development PartnerFirst CIBER spin-off company providing epigenetic diagnostic tools, novel drug characterization, and translational research stimulation to improve health and wellbeing.
• European Commission - Horizon ProgramscoreStrategic or Co-development PartnerMultiple European-funded research projects including H2020, ERC, Horizon Europe, IMI2, and various joint technology programs with roles ranging from coordinator to partner to affiliated entity.
• European Research Executive Agency (REA)coreStrategic or Co-development PartnerFunding agency for multiple CIBER research projects including CoDIET and NUTRIMIND under Horizon programs.
• IMPaCT Infrastructure PartnerscoreStrategic or Co-development PartnerCIBER coordinates two of three IMPaCT (Infrastructure for Precision Medicine associated with Science and Technology) programs: Predictive Medicine (IMPaCT Cohort) and Genomic Medicine (IMPaCT Genomic).
• Biobank Platforms NetworkcoreStrategic or Co-development PartnerCollaboration with ISCIII Biobanks and Biomodels Platform, Pulmonary Biobank Consortium, and National Biobanks Network for biological sample provision and quality control.
• CIBERDZD (German Diabetes Center)minorStrategic or Co-development PartnerJoint webinar series on interorgan communication in metabolism between CIBERDEM and German Diabetes Center.

Scale indicators6 records

Recent moves13 records

Expansion highlights6 records

Direct peers

• INSERM: The French national institute for health and medical research is the closest structural analogue to CIBER — a publicly funded national biomedical research network coordinating research groups across universities and hospitals, organized by thematic areas, with comparable scale and translational mandate.
• EATRIS - European Infrastructure for Translational Medicine: A European research infrastructure consortium coordinating biomedical translational capabilities across member institutions — structurally analogous to CIBER's network model and a participant in many of the same Horizon Europe funding programs that CIBER accesses.
• CNIC - Centro Nacional de Investigaciones Cardiovasculares: Spain's national cardiovascular research center shares CIBER's institutional parent (ISCIII) and operates with a comparable public-research-center model, including cardiovascular translational research that parallels CIBERCV's disease focus.
• Centre for Genomic Regulation (CRG): A Barcelona-based biomedical research institute with mixed public funding and a heavy focus on genomics, proteomics, and bioinformatics — overlapping directly with CIBER's bioinformatics and precision medicine capabilities across multiple thematic areas.
• Helmholtz Association: Germany's largest research association networks 18 research centers across health, energy, and related fields with EU and federal co-financing, structurally comparable to CIBER's multi-institution consortium model with mixed public funding.
• Institut Pasteur: A French non-profit foundation with deep biomedical research infrastructure spanning infectious disease, immunology, and genomics; comparable to CIBER's network model through its international research network, biobanking programs, and translational pipeline.
• Francis Crick Institute: A large biomedical research institute in London conducting discovery science across cancer, infection, and neuroscience with public and charitable funding — comparable to CIBER's translational research scale and multi-disease platform approach.
• CNIO - Centro Nacional de Investigaciones Oncológicas: Spain's national cancer research center operates as a government-funded biomedical research institute with a similar ISCIII ecosystem footprint; partial overlap with CIBERONC as a CIBER thematic area covering oncology research, IP generation, and translational programs.

Broad incumbents

• Max Planck Society: Germany's largest publicly funded basic research organization operates a federation of institutes across life sciences and biomedical disciplines, comparable in scientific breadth, scale, and public funding model to CIBER's consortium structure.
• Karolinska Institutet: Sweden's premier medical university operates one of Europe's largest biomedical research portfolios with extensive translational research programs — comparable to CIBER in research breadth and disease-area coverage, and a natural competitor for European grant funding.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/CIBER_ISCIII
• LinkedInlinkedin.com/company/ciberisciii

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centro de Investigación Biomédica en Red